B
명문제약
017180KOSPI57.5 / 100
Reference Date: 2026-09-08
Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Rose 7.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Myungmoon Pharmaceutical operates in two main segments: pharmaceutical/biotech and services. The company generates revenue through the production and distribution of key products such as cholesterol treatment medications. In 2025, consolidated sales reached approximately 195,247 million won, showing growth in both domestic and export markets.
Number of Employees
309people
Average Salary
63.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
21.84Industry Average 15.003.0Point
Higher than industry avg (caution)
PBR
0.40Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
1.37Industry Average 8.001.0Point
Well below industry avg
Debt Ratio
68.58Industry Average 100.005.0Point
Lower than industry avg (good)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲7.3% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲177.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -2.6% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (21%)
Current 1,245Won52-week high 1,94552-week low 1,057
1-month return5.0Point
1m +7.33% (rising)
Volume trend6.0Point
Volume surge
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-07
- Neutral반기보고서 (2026.06)2026-08-14
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-12